BridgeBio Pharma, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Neil Kumar
- Full Time Employees
- 999
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 3160 Porter Drive Palo Alto CA United States of America 94304
- IPO Date
- Jun 27, 2019
- CIK
- 0001743881
- Website
- bridgebio.com
- Similar Companies
- Business
- BridgeBio Pharma, Inc. is a biopharmaceutical company focused on developing and delivering transformative medicines to patients with genetic diseases and cancers. The company’s core products and services include the research, development, and commercialization of novel drug candidates targeting genetic disorders and oncology indications. BridgeBio’s portfolio encompasses multiple clinical and preclinical programs across areas such as rare diseases, oncology, and precision medicine, featuring therapies in pipeline development as well as marketed products. BridgeBio operates primarily in the United States but also engages in global clinical trials and partnerships to expand its reach. Founded in 2015 and headquartered in Palo Alto, California, the company leverages its drug development expertise through subsidiaries and strategic alliances with academic institutions, pharmaceutical companies, and biotechnology firms. Recent major company developments include significant funding rounds to advance its pipeline programs; strategic partnerships to enhance its research capabilities; acquisitions aimed at broadening its therapeutic areas and bolstering its technology platforms; and the launch of new investigational drugs targeting underserved genetic conditions. These moves have reinforced BridgeBio’s commitment to advancing precision medicine and expanding its impact in the rare disease and oncology markets. The company continues to evolve its pipeline with a focus on rapid clinical development and commercialization of targeted therapies to improve patient outcomes.
Company News
BridgeBio to Present New Data on the Impact of Oral Infigratinib on Medical Complications in Achondroplasia at the Annual ESPE Meeting 2026
Trump's MFN Push Goes Beyond Big Pharma, Adds 9 Mid-Sized Drugmakers
4 Rare Disease Drugmakers With Strong Long-Term Growth Prospects
BridgeBio to Participate in September Investor Conferences
BridgeBio Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for Americans
Acoramidis Demonstrates Reversal of Cardiac Structural Disease Progression and Functional Decline and Significantly Increases Days Alive and Free from Hospitalization in ATTR-CM
BridgeBio Announces First Participant Dosed in ASCEND-ATTR, a Phase 3b/4 Study Evaluating the Long-Term Effects of Acoramidis on Disease Regression in ATTR-CM
BridgeBio Q2 Sales Jump 120% as Attruby Drives Commercial Momentum
Why BBIO Rose 24% in Three Months and Whether the Rally Can Continue
Is BBIO a Buy as Fast Sales Growth Meets a Steep Valuation Premium?
BridgeBio to Present New Acoramidis Data from Open-Label Extension Analyses in ATTR-CM at ESC Congress 2026
BridgeBio Stock Has Soared 29% in Just 3 Months. Here's Why Wall Street Thinks It Could Go Even Higher.
BridgeBio Pharma Announces Pricing of Oversubscribed Secondary Offering that Diversifies its Institutional Shareholder Base
BridgeBio Pharma Announces Launch of Secondary Offering of Common Stock on Behalf of an Existing Shareholder
BridgeBio Pharma Q2 Earnings Call Highlights
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BridgeBio Q2 Earnings Miss, Revenues Beat as Attruby Sales Surge
BridgeBio: Attruby Delivers In Q2, Expect Three New Launches In 12 Months
4 Biotech Stocks With Major Second-Half Pipeline Catalysts This Year
BridgeBio Pharma, Inc. (BBIO) Q2 2026 Earnings Call Transcript